Pular para o conteúdo
Merck
Todas as fotos(1)

Documentos Principais

RAB0521

Sigma-Aldrich

Bovine IL2 / Interleukin-2 ELISA Kit

for serum, plasma and cell culture supernatants

Faça loginpara ver os preços organizacionais e de contrato
Todas as fotos(1)

About This Item

Código UNSPSC:
41116158
NACRES:
NA.32

reatividade de espécies

bovine

embalagem

kit of 96 wells (12 strips x 8 wells)

técnica(s)

ELISA: suitable

entrada

sample type serum
sample type cell culture supernatant(s)
sample type plasma

assay range

inter-assay cv: <10%
intra-assay cv: <12%
sensitivity: 0.2 ng/mL

método de detecção

colorimetric

Condições de expedição

wet ice

temperatura de armazenamento

−20°C

Informações sobre genes

bovine ... IL2(280822)

Categorias relacionadas

Descrição geral

This ELISA antibody pair detects bovine Interleukin-2.

Aplicação

For research use only. Not for use in diagnostic procedures.
Please refer to the attached General ELISA KIT Procedure (sandwich, competitive & Indirect ELISA)

Outras notas

A sample Certificate of Analysis is available for this product.
Please type the word sample in the text box provided for lot number.

Componentes do kit também disponíveis separadamente

Nº do produto
Descrição
SDS
  • RABTMB3ELISA Colorimetric TMB Reagent (HRP Substrate, Item H)SDS
  • RABSTOP3ELISA Stop Solution (Item I)SDS
  • RABELADBELISA 5X Assay/Sample Diluent Buffer B (Item E1)SDS
  • RABELADCELISA 1X Assay/Sample Diluent Buffer C (Item L)SDS
  • RABWASH420X Wash Buffer (Item B)SDS

Pictogramas

Corrosion
GHS05

Palavra indicadora

Warning

Frases de perigo

H290

Declarações de precaução

P234 - P390

Classificações de perigo

Met. Corr. 1

Código de classe de armazenamento

8A - Combustible corrosive hazardous materials

Ponto de fulgor (°F)

Not applicable

Ponto de fulgor (°C)

Not applicable

Certificados de análise (COA)

Busque Certificados de análise (COA) digitando o Número do Lote do produto. Os números de lote e remessa podem ser encontrados no rótulo de um produto após a palavra “Lot” ou “Batch”.

Já possui este produto?

Encontre a documentação dos produtos que você adquiriu recentemente na biblioteca de documentos.

Visite a Biblioteca de Documentos

Pratiksha Gulati et al.
Clinical cancer research : an official journal of the American Association for Cancer Research, 24(16), 3981-3993 (2018-05-12)
Purpose: Combination therapy of adoptively transferred redirected T cells and checkpoint inhibitors aims for higher response rates in tumors poorly responsive to immunotherapy like malignant pleural mesothelioma (MPM). Only most recently the issue of an optimally active chimeric antigen receptor
Tatsuo Matsuda et al.
Clinical cancer research : an official journal of the American Association for Cancer Research, 24(21), 5357-5367 (2018-05-04)
Purpose: Current evolution of cancer immunotherapies, such as immune checkpoint blockade, has implicated neoantigens as major targets of anticancer cytotoxic T cells. Adoptive T-cell therapy with neoantigen-specific T-cell receptor (TCR)-engineered T cells would be an attractive therapeutic option for advanced
Francesco Nannini et al.
Scientific reports, 10(1), 19168-19168 (2020-11-07)
Antibody phage display is a powerful platform for discovery of clinically applicable high affinity monoclonal antibodies against a broad range of targets. Libraries generated from immunized animals offer the advantage of in vivo affinity-maturation of V regions prior to library
Liping Qiu et al.
Small (Weinheim an der Bergstrasse, Germany), 14(15), e1703539-e1703539 (2018-03-02)
The activation of tumor-specific effector immune cells is key for successful immunotherapy and vaccination is a powerful strategy to induce such adaptive immune responses. However, the generation of effective anticancer vaccines is challenging. To overcome these challenges, a novel straight-forward
Zhengping Hu et al.
Scientific reports, 8(1), 217-217 (2018-01-11)
The increased PD-L1 induces poorer prognosis in melanoma. The treatment with PD-1/PD-L1 antibodies have a low response rate. The combination immunotherapies are the encouraging drug development strategy to receive maximal therapeutic benefit. In this study, we investigated the enhanced antitumor
Exibir todos os documentos relacionados

Nossa equipe de cientistas tem experiência em todas as áreas de pesquisa, incluindo Life Sciences, ciência de materiais, síntese química, cromatografia, química analítica e muitas outras.

Entre em contato com a assistência técnica